Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Shares (2020 - 2025)

Historic Preferred Shares for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Q3 2025 value amounting to $127.7 million.

  • Viridian Therapeutics, Inc.\DE's Preferred Shares changed 0.0% to $127.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.7 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $127.7 million for FY2024, which is 45.53% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Preferred Shares stood at $127.7 million, which was down 0.0% from $127.7 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Preferred Shares peaked at $145.8 million during Q3 2021, and registered a low of $78.2 million during Q1 2023.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Preferred Shares had a median value of $127.7 million in 2024 and averaged $110.4 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Preferred Shares tumbled by 4137.62% in 2022, and later skyrocketed by 6396.88% in 2024.
  • Viridian Therapeutics, Inc.\DE's Preferred Shares (Quarter) stood at $118.2 million in 2021, then dropped by 27.67% to $85.5 million in 2022, then soared by 50.09% to $128.3 million in 2023, then dropped by 0.46% to $127.7 million in 2024, then changed by 0.0% to $127.7 million in 2025.
  • Its last three reported values are $127.7 million in Q3 2025, $127.7 million for Q2 2025, and $127.7 million during Q1 2025.